Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8752W HIGH $2.24
Volume
1.71 M
Value Traded
530.21 K
Short % Float
19.56%
+7.87%Week
-25.75%1 Month
+3.79%3 Month
-26.74%6 Month
-91.89%5 Year
-92.9%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
99.30 M
EPS (TTM)
-0.45
P/E Ratio
-
Ent. Value
64.48 M
Total Shares
72.48 M
Float Shares
67.58 M
Insiders
6.76%
Institutions
40.70%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BMEA Catalyst Timeline
Dated clinical, regulatory and corporate events for Biomea Fusion, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biomea Fusion, Inc.
394Total events
10Upcoming
72Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteicovamenibTrial
Completion of enrollment in COVALENT-211
insulin-deficient type 2 diabetessource ↗
▲First Patient DosedicovamenibTrial
First participant dosed in OPAL study arm evaluating icovamenib in combination with semaglutide
obesitysource ↗
▲Partnership / LicenseicovamenibCorporate
Research collaboration with University of Leicester initiated
Obesitysource ↗
◆Trial InitiationicovamenibTrial
Enrollment expected to begin in obesity combination trial
Obesitysource ↗
◆Late-BreakericovamenibPresentation
Icovamenib, a Menin Inhibitor, Improves Endogenous Insulin Secretion in Type 1 Diabetes: Results from the COVALENT-112 Study
type 1 diabetessource ↗
◆Poster PresentationicovamenibPresentation
Late-breaking preclinical poster at ADA Scientific Sessions: Menin Inhibitor Icovamenib Activates Mechanisms That Support Metabolic Health (poster #2871-LB)
metabolic healthsource ↗
◆AbstracticovamenibPresentation
Embargo lift and publication of abstracts on Diabetes journal website and Biomea website
diabetessource ↗
◆Oral PresentationicovamenibPresentation
Comprehensive dataset to be presented at ADA Scientific Sessions
type 1 diabetessource ↗
●Enrollment UpdateBMF-650Trial
Expansion of Phase I BMF-650 study to evaluate rapid one-step titration
obesitysource ↗
▲Partnership / LicenseCorporate
Research collaboration with University of Leicester to evaluate icovamenib in combination with semaglutide in obesity
▲Trial InitiationicovamenibTrial
Activation of experimental arm evaluating icovamenib + semaglutide in OPAL study
obesitysource ↗
▲Oral PresentationicovamenibPresentation
52-week follow-up data presented at ADA Scientific Sessions
Type 1 diabetessource ↗
◆Oral PresentationPresentation
Management to participate in upcoming investor conferences with fireside chats
▲Enrollment CompleteicovamenibTrial
Chronic toxicology studies completed for icovamenib
type 1 diabetessource ↗
▲Topline ReadouticovamenibClinical Data
Topline data reported from Phase II COVALENT-112 in T1D
type 1 diabetessource ↗
▲Topline ReadouticovamenibClinical Data
Topline results of COVALENT-112 presented on April 28, 2026
Type 1 Diabetessource ↗
▲Full ResultsicovamenibClinical Data
Positive 52-week results from Phase 2 COVALENT-112 trial showing C-peptide improvement and durability
type 1 diabetessource ↗
◆Topline ReadouticovamenibClinical Data
52-week follow-up data from T1D patients in COVALENT-112 who completed ≥80% dosing
type 1 diabetessource ↗
◆Topline ReadoutBMF-650Clinical Data
Initial 28-day clinical weight-reduction data from Phase I GLP-131 study
obesitysource ↗
●Trial InitiationicovamenibTrial
Planned Phase 2 trial in T1D patients diagnosed within past 3 years to be initiated
type 1 diabetessource ↗
◆Full ResultsicovamenibClinical Data
52-week follow-up data for COVALENT-112 in type 1 diabetes patients
Type 1 diabetessource ↗
◆Trial CompletionBMF-650Trial
Completion of single- and multiple-ascending dose cohorts in GLP-131
obesitysource ↗
▲First Patient DosedicovamenibTrial
First patient dosed in Phase II COVALENT-211 study
type 2 diabetessource ↗
◆Oral PresentationPresentation
BMO Metabolic Health Summit panel discussion on emerging competitors in obesity and metabolic space
▲Trial InitiationicovamenibTrial
Initiated Phase II COVALENT-212 trial of icovamenib in type 2 diabetes on GLP-1 RA therapy
type 2 diabetessource ↗
▲Trial CompletionicovamenibTrial
Completed 52-week follow-up from Phase II COVALENT-112 in type 1 diabetes
type 1 diabetessource ↗
▲Oral PresentationicovamenibPresentation
Oral presentation of 52-week follow-up results from COVALENT-111 at ATTD 2026
type 2 diabetessource ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference virtual presentation
◆Trial InitiationicovamenibTrial
COVALENT-212 Phase II trial of icovamenib in GLP-1 inadequate responders
Type 2 Diabetessource ↗
▲Full ResultsicovamenibClinical Data
52-week safety and efficacy data from COVALENT-111
Type 2 Diabetessource ↗
◆Topline ReadoutBMF-650Clinical Data
28-day weight loss data from Phase I study of BMF-650 in healthy obese patients
obesitysource ↗
▲First Patient DosedicovamenibTrial
First patient dosed in icovamenib combination trial with GLP-1 based therapy
type 2 diabetessource ↗
▼Program DiscontinuationBMF-500DiscontinuedCorporate
BMF-500 study to conclude after dose escalation phase
Relapsed/Refractory Acute Leukemia with FLT3 mutationssource ↗
●Oral PresentationicovamenibPresentation
Dr. Ralph DeFronzo presents 'What Does the Future Hold for Menin Inhibitors and Insulin Sensitizers' at WCIRDC 2025
type 2 diabetessource ↗
▲Oral PresentationicovamenibPresentation
Oral presentation of COVALENT-111 study results at WCIRDC
insulin-deficient type 2 diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How BMEA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | icovamenib | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C53 / 100
Pipeline Score
$193M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
2.1x
rNPV / MCap
Top 13%
Micro Cap(rank 86 of 658)
Percentile Rank
Biomea Fusion, Inc. carries a moderate pipeline score (53/100), with $4.0B risk-adjusted pipeline value, led by BMF-219 in Type 1 Diabetes Mellitus (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BMF-219 Small moleculeCompletedNCT06152042 | Type 1 Diabetes Mellitus | Phase 2 | COMPLETED | 37 | Jul 18, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every BMEA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| icovamenib | type 1 diabetes | Phase 2 | 2026-05-11 | Topline data from the Phase II COVALENT-112 clinical trial evaluating icovamenib in T1D patients were reported from the 52-week.Read More | Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate HighlightsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Erdtmann Rainer MDirector, Officer (See Remarks) | Grant/Award | 452,512 452,512 held | $0.00 | 04/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BMEA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.1 % (-50 %) | 5.63 M | 1.45 M | -31.15% ( -656.96 K) |
BMEA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BMEA ranks across every disease it competes in
Competitive Position is a premium feature
See how BMEA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBMEA News
BMEA▼ -15.3%on this news
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Biomea Fusion has announced the termination of its proposed public offering of securities due to unfavorable market conditions. The decision was made to protect the interests of the company's stockholders. No securities were sold in connection with the offering, which was initially announced on September 22, 2026.
Read more →BMEA▼ -15.3%on this newsshared move
Biomea Fusion Announces Proposed Public Offering of Securities
Biomea Fusion has announced a proposed public offering of its common stock and pre-funded warrants. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase additional shares. The company focuses on developing therapies for diabetes and obesity, aiming to provide transformative treatments. However, uncertainties regarding the offering's completion and terms are noted.
Read more →BMEABiomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion, a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The company will hold one-on-one meetings at Citi's Biopharma Back to School Conference on September 10, 2026, and present at the H.C. Wainwright Annual Global Investment Conference on September 15, 2026. These events highlight Biomea's commitment to advancing therapies for diabetes and obesity.
Read more →BMEA▲ +16.1%on this news· ran to +26% by day 1
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Biomea Fusion has completed enrollment in the COVALENT-211 Phase II trial, evaluating icovamenib for insulin-deficient Type 2 Diabetes patients. The trial enrolled 64 participants and aims to assess glycemic control over a 52-week period. Topline results for the primary endpoint are anticipated in the first quarter of 2027, following promising data from earlier studies.
Read more →BMEABiomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion has initiated a new arm of its OPAL study, dosing the first participant with icovamenib combined with low-dose semaglutide. This study aims to evaluate the effects of this combination on weight loss and various health metrics in individuals who are overweight or obese. The trial will assess whether icovamenib can enhance the efficacy of semaglutide, focusing on broader metabolic health outcomes.
Read more →BMEABiomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion reported its second quarter 2026 financial results, highlighting ongoing enrollment in two Phase II trials for Type 2 diabetes and a Phase I trial for obesity. The company anticipates initial weight reduction data from its BMF-650 trial in Q3 2026. Financially, Biomea reported a net loss of $8.3 million but has a cash runway extending into Q2 2027.
Read more →BMEA▼ -7.3%on this news
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion presented promising new clinical and translational data for icovamenib at the ADA 86th Scientific Sessions. The data highlights potential benefits in muscle preservation, fat reduction, and improvements in glycemic control among type 1 and type 2 diabetes patients. Additionally, Biomea announced the expansion of its Phase I BMF-650 study to optimize dosing and enhance weight loss potential. Overall, the findings support icovamenib's broader therapeutic utility in obesity and diabetes management.
Read more →BMEA▼ -5.1%on this news· ran to -16% by day 3shared move
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion has announced a collaboration with the University of Leicester to evaluate the effects of icovamenib in combination with semaglutide on obesity. This study, part of the OPAL platform trial, aims to assess improvements in physical function and metabolic outcomes. The trial will begin enrollment in Q3 2026, focusing on individuals who are overweight or obese without type 2 diabetes.
Read more →BMEA▼ -6.3%on this news· ran to -21% by day 3
Biomea Fusion to Participate at Upcoming Investor Conferences - May 12, 2026
Biomea Fusion, Inc. announced its participation in upcoming investor conferences, highlighting its focus on developing therapies for diabetes and obesity. The company aims to address metabolic disorders affecting a large portion of the global population. Webcasts of the events will be available for those unable to attend live.
Read more →BMEABiomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion reported its first quarter 2026 financial results, highlighting progress in its clinical trials for icovamenib in type 1 and type 2 diabetes. The company successfully completed chronic toxicology studies and initiated two Phase II trials for type 2 diabetes. Additionally, topline data from the Phase II COVALENT-112 trial showed promising results, with a cash runway projected into early 2027.
Read more →BMEABiomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
Biomea Fusion announced that three abstracts on icovamenib will be presented at the ADA 86th Scientific Sessions. The presentations will showcase data on the investigational oral menin inhibitor's effects on beta cell function in type 1 and type 2 diabetes. The event will take place from June 5-8, 2026, in New Orleans.
Read more →BMEA▼ -11.6%on this news
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Biomea Fusion announced positive results from its Phase 2 COVALENT-112 trial for icovamenib in type 1 diabetes, showing a significant 52% increase in mean C-peptide levels after 12 weeks. The treatment demonstrated durability, with effects largely preserved through Week 52. Icovamenib was well tolerated, and the company plans to advance further trials.
Read more →BMEA▼ -11.6%on this newsshared move
COVALENT-112 Topline Results BIOMEA
Biomea Fusion, Inc. has shared forward-looking statements regarding future business and financial performance. The presentation emphasizes the uncertain nature of these predictions, which are influenced by various risks, including regulatory approvals and market dynamics. Specifically, the discussion touches on the investigational therapies for Type 1 Diabetes and the limitations associated with existing treatment options. A focus is placed on the anticipated clinical trials and the goals of restoring beta cell function, although challenges persist in achieving durable therapeutic outcomes.
Read more →BMEA▲ +15.9%on this news
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Biomea Fusion has announced the dosing of its first patient in the Phase II clinical programs, COVALENT-211 and COVALENT-212, which target type 2 diabetes patients not achieving glycemic control with standard therapies. These studies assess the investigational drug icovamenib, anticipated to deliver topline data by the end of 2026. The trials focus on patients requiring improved glucose management, demonstrating previously observed durability in response. This marks a critical advancement for Biomea as it looks to address unmet medical needs in diabetes treatment.
Read more →BMEA▲ +8%on this news· ran to +21% by day 1
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Biomea Fusion reported its financial results for 2025, highlighting advancements in its diabetes and obesity treatments. The company achieved durable clinical data with icovamenib and initiated two Phase II studies in type 2 diabetes. Additionally, Biomea advanced its next-generation GLP-1 receptor agonist, BMF-650, into a Phase I study, with expectations for multiple data readouts in the coming year.
Read more →BMEA▼ -8.1%on this news· ran to -20% by day 3
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Biomea Fusion presented positive 52-week follow-up results from its Phase II COVALENT-111 study at the ATTD 2026 conference. The study evaluated icovamenib's efficacy, safety, and tolerability in patients with type 2 diabetes. Results showed significant reductions in HbA1c levels, particularly in severe insulin-deficient patients. The company plans to initiate further studies targeting optimal patient populations.
Read more →BMEA▲ +7.6%on this news
st 1 QUARTER 2026 Biomea Fusion Corporate Presentation 1 Legal disclaimer & forward-looking statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These st
Biomea Fusion, Inc. is advancing its clinical programs targeting diabetes and obesity with promising developments in their oral medications, ICOVAMENIB and BMF-650. The company is preparing for significant data readouts in 2026, including two Phase II studies relevant for Type 2 diabetes, where unmet patient needs remain high. Initial results for ICOVAMENIB show potential for beta-cell restoration, and ongoing trials for BMF-650 target weight reduction in obese patients. Biomea retains full rights to its products and is adequately funded for upcoming milestones.
Read more →BMEABiomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion, Inc. (Nasdaq: BMEA) has announced its participation in several upcoming investor conferences including the Oppenheimer 36th Annual Healthcare Life Sciences Conference, The Citizens Life Sciences Conference, and the BMO Metabolic Health Summit. At these events, the company will present its work and engage in one-on-one meetings with investors. Biomea is involved in developing therapies for diabetes and obesity, which are significant global health challenges. The presentations will also be available via webcast for those unable to attend in person.
Read more →About Biomea Fusion, Inc.
Headquarters1599 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
BIOPHARMAWATCH ELITE PLUS
Trade the next BMEA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime